Human H9 cells proliferation is differently controlled by Vasoactive Intestinal Peptide or Peptide Histidine Methionine: Implication of a GTP-insensitive form of VPAC 1 receptor

Journal of Neuroimmunology

Volumn 158, Issue 1-2, 2005, Pages 94-105

  Goursaud, Stephanie ^a   Pineau, Nicolas ^a   Becq Giraudon, Laetitia ^a   Gressens, Pierre ^b   Muller, Jean Marc ^a   Janet, Thierry ^a  

^a 40 Avenue du Recteur Pineau   (France)

^b INSERM   (France)

Author keywords

Adenylate cyclase; GTP insensitive binding sites; PHM; Proliferation; VIP; VPAC receptors

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATE; PEPTIDE HISTIDINE METHIONINE; PERTUSSIS TOXIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENINE; ADENYLATE CYCLASE; ANALYSIS OF VARIANCE; BLOTTING, SOUTHERN; BROMODEOXYURIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION; GUANOSINE TRIPHOSPHATE; GUANYLYL IMIDODIPHOSPHATE; HUMANS; IMINES; IODINE ISOTOPES; LYMPHOMA; PEPTIDE FRAGMENTS; PEPTIDE PHI; PERTUSSIS TOXIN; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 10344234220     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.08.018     Document Type: Article

References (60)

1. B. Bardrum, B. Ottesen, and J. Fahrenkrug Peptides PHI and VIP: comparison between vascular and nonvascular smooth muscle effect in rabbit uterus Am. J. Physiol. 251 1986 E48 E51
2. E. Bofill-Cardona, O. Kudlacek, Q. Yang, H. Ahorn, M. Freissmuth, and C. Nanoff Binding of calmodulin to the D2-dopamine receptor reduces receptor signalling by arresting the G protein activation switch J. Biol. Chem. 275 2000 32672 32680
3. F. Boudard, and M. Bastide Inhibition of mouse T-cell proliferation by CGRP and VIP: effects of the neuropeptides on IL-2 production and cAMP synthesis J. Neurosci. Res. 29 1991 29 41
4. A. Cauvin, A. Vandermeers, M.C. Vandermeers-Piret, P. Robberecht, and J. Christophe Variable distribution of three molecular forms of peptide histidine isoleucinamide in rat tissues: identification of the large molecular form as peptide histidine valine-(1-42) Endocrinology 125 1989 2645 2655
5. N.D. Christofides, Y. Yiangou, M.A. Blank, K. Tatemoto, J.M. Polak, and S.R. Bloom Are peptide histidine isoleucine and vasoactive intestinal peptide co-synthesised in the same pro-hormone? Lancet 2 1982 1398
6. Y. Daaka, L.M. Luttrell, and R.J. Lefkowitz Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A Nature 390 1997 88 91
7. M. Delgado, C. Martinez, M.C. Johnson, R.P. Gomariz, and D. Ganea Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-1 and VIP-2) mRNA in murine lymphocytes J. Neuroimmunol. 68 1996 27 38
8. M. Delgado, D. Pozo, C. Martinez, E. Garrido, J. Leceta, J.R. Calvo, and R.P. Gomariz Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages Regul. Pept. 62 1996 161 166
9. + thymocytes from glucocorticoid-induced apoptosis Blood 87 1996 5152 5161
10. M. Delgado, E. Munoz-Elias, R.P. Gomariz, and D. Ganea Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies J. Immunol. 162 1999 1707 1716
11. U. Ernström, G. Gafvelin, and V. Mutt Rescue of thymocytes from cell death by vasoactive intestinal peptide Regul. Pept. 57 1995 99 104
12. J. Fahrenkrug, J.H. Pedersen, Y. Yamashita, B. Ottensen, T. Hokfelt, and J.M. Lundberg Occurence of VIP and peptide HM in human pancreas and their influence on pancreatic endocrine secretion in man Regul. Pept. 18 1987 51 61
13. P. Gourlet, P. Robberecht, and J. Christophe Molecular characterization of helodermin-preferring VIP receptors in SUP-T1 lymphoma cells: evidence for receptor glycosylation J. Recept. Res. 11 1991 831 848
14. P. Gourlet, A. Vandermeers, J. Van Rampelbergh, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors Ann. N.Y. Acad. Sci. 865 1998 247 252
15. I. Gozes, and S. Furman VIP and drug design Curr. Pharm. Des. 9 2003 483 494
16. P. Gressens, J.M. Hill, I. Gozes, M. Fridkin, and D.E. Brenneman Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos Nature 362 1993 155 158
17. P. Gressens, J.M. Hill, B. Paindaveine, I. Gozes, M. Fridkin, and D.E. Brenneman Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse J. Clin. Invest. 94 1994 2020 2027
18. A.J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J.R. Pisegna, S.R. Rawlings, P. Robberecht, S.I. Said, S.P. Sreedharan, S.A. Wank, and J.A. Waschek International Union of Pharmacology. XVIII: nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide Pharmacol. Rev. 50 1998 265 270
19. H. Hashimoto, T. Ishihara, R. Shigemoto, K. Mori, and S. Nagata Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide Neuron 11 1993 333 342
20. N. Hayez, I. Harfi, R. Lema-Kisoka, M. Svoboda, F. Corazza, and E. Sariban The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells J. Neuroimmunol. 149 2004 167 181
21. J.M. Hill, D.V. Agoston, P. Gressens, and S.K. Mccune Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: relation to ontogenic events J. Comp. Neurol. 342 1994 186 205
22. J.M. Hill, S.J. Lee, J.R. Dibbern, M. Fridkin, I. Gozes, and D.E. Brenneman Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth Neuroscience 93 1999 783 791
23. Y. Ichiki, K. Kitamura, K. Kangawa, M. Kawamoto, H. Matsuo, and T. Eto Organ distribution and characterization of porcine peptides (VIP, CGRP and PHI) that increase cAMP in rat platelets Biochem. Biophys. Res. Commun. 187 1992 1587 1593
24. C. Ishioka, A. Yoshida, H. Kimata, and H. Mikawa Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells Clin. Exp. Immunol. 87 1992 504 508
25. N. Itoh, K. Obata, N. Yanaihara, and H. Okamoto Human preprovasoactive intestinal polypeptide contains a novel PHI-like peptide, PHM27 Nature 304 1983 547 549
26. S.A. Joshi, K.P.K. Fan, V.W.S. Ho, and Y.H. Wong Chimeric Galpha (q) mutants harboring the last five carboxy-terminal residues of Galpha (i2) or Galpha (o) are resistant to pertussis toxin-catalysed ADP-ribosylation FEBS Lett. 441 1998 67 70
27. N. Kanda, and S. Watanabe Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells Biochem. Pharmacol. 62 2001 495 507
28. M. Laburthe, and A. Couvineau Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP Regul. Pept. 108 2002 165 173
29. M. Laburthe, A. Couvineau, C. Rouyer-Fessard, and L. Moroder Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptor from colonic epithelium: comparison with rat intestinal receptors Life Sci. 36 1985 991 995
30. V. Lelievre, N. Pineau, J. Du, C.H. Wen, T. Nguyen, T. Janet, J.M. Muller, and J.A. Waschek Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation J. Biol. Chem. 273 1998 19685 19690
31. X. Luo, W. Zeng, X. Xu, S. Popov, I. Davignon, T.M. Wilkie, S.M. Mumby, and S. Muallem Alternate coupling of receptors to Gs and Gi in pancreatic and submandibular gland cells J. Biol. Chem. 274 1999 17684 17690
32. D.L. Mann, S.J. O'Brien, D.A. Gilbert, Y. Reid, M. Popovic, E. Read-Connole, R.C. Gallo, and A.F. Gazdar Origin of the HIV-susceptible human CD4+ cell line H9 AIDS Res. Hum. Retrovir. 5 1989 253 255
33. J.L. Martin, K. Rose, G.J. Hughes, and P.J. Magistretti [mono[125I]iodo-Tyr10,MetO17]-vasoactive intestinal polypeptide. Preparation, characterization, and use for radioimmunoassay and receptor binding J. Biol. Chem. 261 1986 5320 5327
34. R. Minakami, N. Jinnai, and H. Sugiyama Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro J. Biol. Chem. 272 1997 20291 20298
35. M. Morfis, A. Christopoulos, and P.M. Sexton RAMPs: 5 years on, where to now? Trends Pharmacol. Sci. 24 2003 596 601
36. K.W. Nowak, and L.K. Malendowicz Steroidogenic effect of peptide histidine-isoleucine (PHI) in vitro: comparison with VIP Endocr. Res. 24 1998 759 762
37. S. Nurko, B.M. Dunn, and S. Rattan Peptide histidine isoleucine and vasoactive intestinal polypeptide cause relaxation of opossum internal anal sphincter via two distinct receptors Gastroenterology 96 1989 403 413
38. M.S. O'Dorisio, C.L. Wood, G.D. Wenger, and L.M. Vassalo Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI) J. Immunol. 134 1985 4078 4086
39. K. Ogi, Y. Miyamoto, Y. Masuda, Y. Habata, M. Hosoya, T. Ohtaki, Y. Masuo, H. Onda, and M. Fujino Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor Biochem. Biophys. Res. Commun. 196 1993 1511 1521
40. C.A. Ottaway Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells Immunology 62 1987 291 297
41. R. Pankhaniya, N. Jabrane-Ferrat, G.O. Gaufo, S.P. Sreedharan, P. Dazin, J. Kaye, and E.J. Goetzl Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes FASEB J. 12 1998 119 127
42. S.K. Park, T.A. Olson, N. Ercal, M. Summers, and M.S. O'Dorisio Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets Blood 87 1996 4629 4635
43. S. Paul, J. Chou, and E. Kubota High affinity peptide histidine isoleucine-preferring receptors in rat liver Life Sci. 41 1987 2373 2380
44. N. Pineau, V. Lelievre, S. Goursaud, S. Hilairet, J.A. Waschek, T. Janet, and J.M. Muller The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes Neuropeptides 35 2001 117 126
45. D. Pozo, M. Delgado, C. Martinez, J.M. Guerrero, J. Leceta, R.P. Gomariz, and J.R. Calvo Immunobiology of vasoactive intestinal peptide (VIP) Immunol. Today 21 2000 7 11
46. s in HEK293 cells transfected with the human VPAC1 receptor Biochem. Biophys. Res. Commun. 272 2000 922 928
47. S.P. Sreedharan, D.R. Patel, J.X. Huang, and E.J. Goetzl Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor Biochem. Biophys. Res. Commun. 193 1993 546 553
48. M. Svoboda, M. Tastenoy, J. Van Rampelbergh, J.F. Goossens, P. De Neef, M. Waelbroeck, and P. Robberecht Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts Biochem. Biophys. Res. Commun. 205 1994 1617 1624
49. J. Szecowka, K. Tatemoto, V. Mutt, and S. Efendic Interaction of a newly isolated intestinal polypeptide (PHI) with glucose and arginine to effect the secretion of insulin and glucagon Life Sci. 26 1980 435 438
50. K. Takahashi, S. Nakanishi, and S. Imamura Direct effects of cutaneous neuropeptides on adenylyl cyclase activity and proliferation in a keratinocyte cell line: stimulation of cyclic AMP formation by CGRP and VIP/PHM, and inhibition by NPY through G protein-coupled receptors J. Invest. Dermatol. 101 1993 646 651
51. S. Teresi, F. Boudard, and M. Bastide Effect of calcitonin gene-related peptide and vasoactive intestinal peptide murine CD4 and CD8 T cell proliferation Immunol. Lett. 50 1996 105 113
52. M. Trejter, J.B. Warchol, R. De Caro, R. Brelinska, G.G. Nussdorfer, and L.K. Malendowicz Studies on the involvement of endogenous neuropeptides in the control of thymocyte proliferation in the rat Histol. Histopathol. 16 2001 155 158
53. D.L. Tse, R.T. Pang, A.O. Wong, S.M. Chan, H. Vaudry, and B.K. Chow Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine Endocrinology 143 2002 1327 1336
54. J.T. Turner, S.B. Jones, and D.B. Bylund A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29 Peptides 7 1986 849 854
55. D. Wang, W. Sadee, and J.M. Quillan Calmodulin binding to G protein-coupling domain of opioid receptors J. Biol. Chem. 274 1999 22081 22088
56. J.A. Waschek, D.T. Bravo, and M.L. Richards High levels of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells Regul. Pept. 60 1995 149 157
57. H. Watanobe, and K. Takebe A further study on the stimulatory effect of peptide histidine methionine on growth hormone secretion in acromegaly: a dose-related study and a comparison with vasoactive intestinal peptide Neuropeptides 23 1992 115 119
58. M. Xia, G.O. Gaufo, Q. Wang, S.P. Sreedharan, and E.J. Goetzl Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors J. Immunol. 157 1996 1132 1138
59. Y. Yiangou, R. Serrano, S.R. Bloom, J. Pena, and H. Festenstein Effects of prepro-vasoactive intestinal peptide-derived peptides on the murine immune response J. Neuroimmunol. 29 1990 65 72
60. Y. Zhang, R. Mahendran, L.L. Yap, K. Esuvaranathan, and H.E. Khoo The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells Biochem. Pharmacol. 63 2002 273 282